Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v6-EN | Version v3-EN | |
---|---|---|
Language | English | English |
Date Updated | 2020-09-18 | 2020-06-30 |
Drug Identification Number | 02189054 | 02189054 |
Brand name | BREVICON 1/35 TABLETS (21-DAY PACK) | BREVICON 1/35 TABLETS (21-DAY PACK) |
Common or Proper name | BREVICON 21 | BREVICON 21 |
Company Name | PFIZER CANADA ULC | PFIZER CANADA ULC |
Ingredients | NORETHINDRONE ETHINYL ESTRADIOL | NORETHINDRONE ETHINYL ESTRADIOL |
Strength(s) | 1MG 0.035MG | 1MG 0.035MG |
Dosage form(s) | TABLET | TABLET |
Route of administration | ORAL ORAL | ORAL ORAL |
Packaging size | 21's | 21's |
ATC code | G03AA | G03AA |
ATC description | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | ||
Actual start date | 2020-06-29 | 2020-06-29 |
Estimated end date | Unknown | 2020-10-09 |
Actual end date | ||
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | Limited amount of product expected to be available in Q1 2021. Recovery expected in Q2 2021. | Limited inventory available and on preventative allocation. |
Health Canada comments |